Lockdowns during the COVID-19 pandemic had a disruptive effect on medical education when they prevented medical students accessing real patients. To address this, we piloted 35 medical students at ...
Key points: Skeletal muscle energy requirements increase at birth but little is known regarding the development of mitochondria that provide most of the cellular energy as ATP. Thyroid hormones are known regulators of adult metabolism and are important in driving several aspects of fetal development, including muscle fibre differentiation. Mitochondrial density and the abundance of mitochondrial membrane proteins in skeletal muscle increased during late gestation. However, mitochondrial functional capacity, measured as oxygen consumption rate, increased primarily after birth. Fetal hypothyroidism resulted in significant reductions in mitochondrial function and density in skeletal muscle before birth. Mitochondrial function matures towards birth and is dependent on the presence of thyroid hormones, with potential implications for the health of pre‐term and hypothyroid infants. Birth is a significant metabolic challenge with exposure to a pro‐oxidant environment and the increased energy demands for neonatal survival. This study investigated the development of mitochondrial density and activity in ovine biceps femoris skeletal muscle during the perinatal period and examined the role of thyroid hormones in these processes. Muscle capacity for oxidative phosphorylation increased primarily after birth but was accompanied by prepartum increases in mitochondrial density and the abundance of electron transfer system (ETS) complexes I–IV and ATP‐synthase as well as by neonatal upregulation of uncoupling proteins. This temporal disparity between prepartum maturation and neonatal upregulation of mitochondrial oxidative capacity may protect against oxidative stress associated with birth while ensuring energy availability to the neonate. Fetal thyroid hormone deficiency reduced oxidative phosphorylation and prevented the prepartum upregulation of mitochondrial density and ETS proteins in fetal skeletal muscle. Overall, the data show that mitochondrial function matures over the perinatal period and is dependent on thyroid hormones, with potential consequences for neonatal viability and adult metabolic health.
Introduction Immune checkpoint inhibitors have significantly improved the prognosis for patients with certain malignancies, however they can also be associated with diverse autoimmune organ toxicities, including those affecting the kidney. Case Presentation A 75-year-old man was referred to the nephrology team with a progressive decline in kidney function over a three-month period. His medical history included a diagnosis of non-small cell lung cancer for which he had been treated with pembrolizumab immunotherapy for the past 18 months (15 cycles). At referral, serum creatinine had risen from a baseline of 140 µmol/L to 208 µmol/L. Urinalysis showed blood and protein and his urine protein creatinine ratio was 457 mg/mmol. An autoimmune screen yielded a positive anti-glomerular basement membrane (Anti-GBM) antibody result (23 iu/L, normal range <7). He underwent a kidney biopsy. Light microscopy demonstrated focal and necrotizing crescentic glomerulonephritis and an eosinophilic tubulo-interstitial nephritis. Immunofluorescence revealed linear IgG deposition along glomerular basement membranes. The patient did not have any clinical or radiographic evidence of pulmonary haemorrhage. A diagnosis of anti-GBM glomerulonephritis was made and the patient received treatment with corticosteroids, seven cycles of plasma exchange, oral cyclophosphamide (total dose 3.3g) and two intravenous doses of 1g rituximab. The patient achieved a negative anti-GBM status within one week of presentation. Despite treatment for anti-GBM disease and cessation of pembrolizumab, his kidney function continued to decline, and his cancer progressed. Six months after diagnosis, he presented unwell to hospital and received treatment for a presumed chest infection. Unfortunately, his condition deteriorated during this inpatient stay and he passed away peacefully (6.7 months after induction treatment). Conclusion This case demonstrates a rare but important diagnosis of anti-GBM disease during pembrolizumab therapy. It highlights the challenges of managing immunosuppression and chemotherapy options in patients who are frail and with impaired kidney function.
Renin-angiotensin-aldosterone inhibitors (RAASi) improve outcomes in patients with heart failure with reduced ejection fraction (HFrEF), but their use is often limited by hyperkalaemia in chronic kidney disease (CKD) patients. This double-blind, placebo-controlled, randomised trial evaluated whether sodium zirconium cyclosilicate (SZC) enables RAASi up-titration in HFrEF patients with CKD stages 3–5 and serum potassium of 5.0–5.5 mmol/L over 14 weeks. The primary binary outcome was defined as achieving the target dose of RAAS inhibition therapy without reaching hyperkalaemia (serum potassium ≥5.6 mmol/L) over 14 weeks or otherwise. Participants ( n = 112) were randomised 1:1 to receive sodium zirconium cyclosilicate (SZC) or placebo. The per-protocol (PP) analyses included 43 out of 53 (81%) in the SZC arm and 53 out of 59 participants (90%) in the placebo arm; the intention-to-treat (ITT) analyses included all 112. At the end of the trial, 24 of 43 participants (56%) in the SZC group achieved the target RAASi dose without developing hyperkalaemia compared with 15 of 53 patients (28%) in the placebo group (PP analysis, p = 0.006, ITT analysis, p = 0.007,). Participants in the SZC group were 3 times more likely to reach the target dose without reaching potassium 5.6 mmol/L (OR = 3.16; 95% CI 1.35–7.39; p = 0.008) than in the placebo group (ITT analysis). No significant differences in adverse events between the two groups were observed. SZC appears to safely support rapid RAASi optimisation in HFrEF patients with CKD. This trial was funded by AstraZeneca via Externally Sponsored Scientific Research grant ESR-19-20174. Trial Registration: Clinicaltrials.gov NCT05004363 and EudraCT number 2020-002946-18.